Immunomodulatory drugs have the function of regulating and enhancing the cellular immune function of the human body and can promote the maturation of T-lymphocytes.

Pharmacodynamics: This product is an immunomodulatory drug. It has the function of regulating and enhancing the cellular immune function of the human body and can promote the maturation of T-lymphocytes.

This product is a fluoroquinolone antibacterial drug with a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacteria. It acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death. It has effects on both Gram-positive and Gram-negative bacteria. Bacteria are not easy to develop resistance to this product, and there is no cross-resistance between similar drugs and antibiotics.

This product is a semi-synthetic 14-membered macrolide antibiotic. The antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, and stronger than erythromycin against Legionella pneumophila. The antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor ("P" position), blocking the transfer RNA (t-RNA) binding to the "P" position, and also blocking the transfer of the polypeptide chain from the acceptor position ("A" position) to the "P" position, thereby inhibiting bacterial protein synthesis.

This product is a new type of fluoroquinolone antibacterial drug, which mainly exerts its antibacterial effect by inhibiting the activity of bacterial DNA helicase and topoisomerase IV and hindering bacterial DNA replication. It is effective against aerobic bacteria, general anaerobes, and anaerobic Gram-positive and Gram-negative bacteria, and has the same antibacterial effect as imipenem and ciprofloxacin, and the antibacterial spectrum is the same as ceftazidime and gentamicin. It has a killing effect on Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus, especially on Pseudomonas aeruginosa in the dormant period, proliferation period, and stable period, with a strength better than ceftazidime and gentamicin; it has a stronger killing effect on Staphylococcus aureus in the dormant period and proliferation period than ceftazidime.